Ibogaine in the treatment of substance dependence.
Level 5 - mechanism / opinion, no new human data
Narrative review of historical, preclinical, and clinical literature
PubMed 23627782 · doi:10.2174/15672050113109990001
What was done
This narrative review summarizes the history, preclinical findings, safety concerns, and clinical research status of ibogaine—a psychoactive alkaloid derived from Tabernanthe iboga—for the treatment of substance dependence. The authors examine the obstacles hindering formal controlled clinical trials, including regulatory classifications such as its Schedule I status in the United States.
What was found
The abstract reports no numerical findings or statistical measures. It notes that preclinical research generally corroborates anecdotal reports indicating that ibogaine attenuates withdrawal symptoms and reduces drug cravings. However, substantive human safety concerns and a lack of robust human clinical data continue to impede its development into an approved therapeutic agent.
Why it matters
The review documents the translational gap between promising preclinical and anecdotal anti-addictive findings for ibogaine and the rigorous human safety and efficacy trials required for medical approval.
Limits
The abstract provides no primary data, systematic search protocol, sample sizes, or quantitative safety parameters. Most available human use has historically occurred outside conventional clinical frameworks, limiting the availability of controlled safety and efficacy data.
Cited by
- supports Ibogaine and DMT are not FDA approved and remain illegal in the United States.